215
Participants
Start Date
September 12, 2018
Primary Completion Date
December 18, 2019
Study Completion Date
December 18, 2019
Semaglutide
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Novo Nordisk Investigational Site, Lausanne
Novo Nordisk Investigational Site, Lausanne
Novo Nordisk Investigational Site, Gland
Novo Nordisk Investigational Site, Geneva
Novo Nordisk Investigational Site, Estavayer-le-Lac
Novo Nordisk Investigational Site, Fribourg
Novo Nordisk Investigational Site, Blonay
Novo Nordisk Investigational Site, Interlaken-Unterseen
Novo Nordisk Investigational Site, Basel
Novo Nordisk Investigational Site, Kleinhüningen
Novo Nordisk Investigational Site, Binningen
Novo Nordisk Investigational Site, Riehen
Novo Nordisk Investigational Site, Solothurn
Novo Nordisk Investigational Site, Olten
Novo Nordisk Investigational Site, Baden
Novo Nordisk Investigational Site, Baden
Novo Nordisk Investigational Site, Bellinzona
Novo Nordisk Investigational Site, Ascona
Novo Nordisk Investigational Site, Chiasso
Novo Nordisk Investigational Site, Lugano
Novo Nordisk Investigational Site, Viganello
Novo Nordisk Investigational Site, Zurich
Novo Nordisk Investigational Site, Zurich
Novo Nordisk Investigational Site, Bülach
Novo Nordisk Investigational Site, Schaffhausen
Novo Nordisk Investigational Site, Nürensdorf
Novo Nordisk Investigational Site, Frauenfeld
Novo Nordisk Investigational Site, Sankt Gallen
Lead Sponsor
Novo Nordisk A/S
INDUSTRY